欧洲纤维疾病治疗市场趋势至2030年

纤维化疾病治疗市场分析

预计未来几年欧洲纤维化疾病治疗市场将大幅增长。纤维化疾病患病率的不断上升、人们对治疗方案的认识不断提高以及医疗技术的进步等因素正在推动这一增长。该地区完善的医疗基础设施和有利的监管环境也有助于市场扩张。此外，欧洲日益增长的老年人口更容易患上纤维化疾病，预计也将推动市场增长。纤维化疾病新型疗法和生物制剂的采用率不断提高是该地区的另一个主要趋势。

纤维化疾病治疗市场规模

2023 年欧洲纤维化疾病治疗市场规模价值 61.8 亿美元，预计到 2031 年将达到 118 亿美元，2024 年至 2031 年预测期内的复合年增长率为 8.42%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

报告指标	细节
预测期	2024 至 2031 年
基准年	2023
历史岁月	2022 (可定制为 2016-2021)
定量单位	收入（单位：十亿美元）、销量（单位：台）、定价（美元）
涵盖的领域	治疗（药物、器官移植、氧疗等）、应用（特发性肺纤维化、肝硬化、肾纤维化、皮肤纤维化等）、最终用户（医院、专科诊所、学术和研究机构等）、分销渠道（医院药房、零售药房等）
覆盖国家	德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其和欧洲其他地区
涵盖的市场参与者	Boehringer Ingelheim International GmbH（德国）、AbbVie Inc.（美国）、Redx Pharma Plc（英国）、Bristol-Myers Squibb Company（美国）、Gilead Sciences, Inc.（美国）、KITHER BIOTECH SRL（意大利）、Verona Pharma plc（英国）、Intercept Pharmaceuticals, Inc.（美国）、Pharmaxis Ltd.（澳大利亚）、Teva Pharmaceutical Industries Ltd.（以色列）、Sandoz International GmbH（奥地利）
市场机会	医疗支出不断增长政府支持举措

纤维化疾病治疗 市场定义

纤维化疾病治疗是指旨在管理和治疗以器官和组织中纤维结缔组织过多或纤维化为特征的疾病的医疗干预和疗法。纤维化是许多慢性疾病的共同特征，可导致器官功能障碍和衰竭。纤维化疾病的治疗策略通常侧重于减少炎症、减缓或阻止纤维化的进展以及控制症状以改善生活质量。

纤维化疾病治疗市场 动态

驱动程序

纤维化疾病患病率不断上升

特发性肺纤维化 (IPF) 和肝纤维化等纤维化疾病的患病率正在上升，这主要是由于人口老龄化和生活方式相关疾病发病率上升等因素。随着人们寿命的延长，患上纤维化疾病的可能性也随之增加，从而推动了对有效治疗的需求并促进了市场增长。此外，吸烟、肥胖和不良饮食等生活方式因素也会导致纤维化疾病的发展，从而进一步增加患病率并推动市场增长。

治疗技术的进步

纤维化疾病治疗领域的技术进步彻底改变了治疗这些疾病的方式。新型疗法和生物制剂提供了更有针对性和更有效的治疗，改善了患者的治疗效果和生活质量。这些进步导致了个性化医疗的转变，即根据患者的具体需求和基因构成为其量身定制治疗方案。这大大提高了治疗效果，是市场增长的主要驱动力。

认知度和诊断率不断提高

医护人员和普通民众对纤维化疾病的认识不断提高，提高了诊断率和早期发现率。这使得患者能够及时接受治疗，从而获得更好的治疗效果并推动市场增长。先进的成像技术和生物标志物测试等诊断能力的提高也有助于早期发现纤维化疾病。随着认识不断提高和诊断方法不断改进，预计会有更多患者寻求治疗，从而进一步推动市场增长。

机会

医疗支出不断增长

人口老龄化国家正在经历医疗保健支出的上升，特别是在纤维化疾病等慢性病的先进治疗方面。支出的上升是由于需要为老龄人口提供高质量的护理，以及医疗技术的进步提供了更有效的治疗选择。随着医疗保健支出的持续增长，预计将推动纤维化疾病治疗市场的增长，为公司提供扩大市场份额的机会。

政府支持举措

欧洲各国政府都在实施政策，以加强医疗服务体系，确保患者能够获得高质量的医疗服务。这些举措包括投资医疗基础设施、增加研发资金以及努力减少获得医疗服务的障碍。因此，纤维化疾病治疗市场预计将受益于这些政府支持性举措，为公司提供扩大市场覆盖范围和开发新治疗方案的机会。

限制/挑战

治疗的副作用

目前许多治疗纤维化疾病的方法，如类固醇和免疫抑制剂，都会引起体重增加、情绪变化和感染风险增加等副作用。这些副作用会导致患者不适和不遵守治疗方案，最终影响纤维化疾病治疗市场。目前治疗纤维化疾病的方法的潜在副作用可能会严重限制其使用，并可能影响市场增长。

治疗费用高昂

纤维化疾病的药物、医疗程序和住院费用可能相当高昂，给患者和医疗保健系统带来经济负担。这种高昂的费用可能会限制许多患者获得治疗的机会，尤其是发展中国家或没有足够保险的患者。纤维化疾病的高昂治疗费用是市场增长的主要制约因素，尤其是在医疗预算有限的国家。

本市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需获取更多市场信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。

纤维化疾病治疗市场范围

纤维化疾病治疗市场根据治疗、应用、最终用户和分销渠道分为四个显著的细分市场。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

治疗

药物
器官移植
氧气治疗
其他的

应用

特发性肺纤维化
肝硬化
肾纤维化
皮肤纤维化
其他的

最终用户

政府组织
医院
学术和研究机构
其他的

分销渠道

医院药房
零售药店
其他的

欧洲纤维化疾病治疗市场区域分析

对市场进行了分析，并按国家、处理、应用、最终用户和分销渠道提供了市场规模见解和趋势，如上所述。

市场覆盖的国家包括德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其和欧洲其他国家。

由于发展中地区的技术进步，德国预计将在市场上占据主导地位并实现显著增长。该国强大的医疗基础设施和对创新的关注，尤其是在纤维化疾病领域，增强了其强大的地位。德国积极主动的研发方式，加上有利的监管环境，使其成为推动整个欧洲纤维化疾病治疗方案的关键参与者。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

纤维化疾病治疗市场份额

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

市场上的一些主要参与者包括：

勃林格殷格翰国际有限公司 (德国)
AbbVie Inc.（美国）
Redx Pharma Plc（英国）
百时美施贵宝公司 (美国)
吉利德科学公司（美国）
KITHER BIOTECH SRL（意大利）
维罗纳制药有限公司 (英国)
Intercept Pharmaceuticals, Inc.（美国）
Pharmaxis Ltd.（澳大利亚）
Teva Pharmaceutical Industries Ltd.（以色列）
Sandoz International GmbH（奥地利）

纤维化疾病治疗市场的最新发展

2023 年 5 月，勃林格殷格翰宣布启动其首创 IL-11 抑制剂抗体 BI 765423 的临床开发。第 1 阶段研究 (NCT05658107) 旨在评估该药物在健康志愿者中的安全性、耐受性和药代动力学。临床前研究表明，这种抗 IL-11 药物有可能抑制甚至逆转各种纤维化疾病中的纤维化
2023 年 5 月，Cumberland Pharmaceuticals Inc. 披露，FDA 已批准一项针对特发性肺纤维化 (IPF) 患者的 II 期研究新药临床试验申请 (IND)，IPF 是最常见的进行性纤维化间质性肺病

SKU-69893

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 2 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 3 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 4 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (VOLUME)

TABLE 5 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (ASP)

TABLE 6 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 7 EUROPE ORGAN TRANSPLANT IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 8 EUROPE OXYGEN THERAPY IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 9 EUROPE OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 10 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 11 EUROPE IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 12 EUROPE HEPATIC CIRRHOSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 13 EUROPE RENAL FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 14 EUROPE CUTANEOUS FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 15 EUROPE OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 16 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 17 EUROPE HOSPITALS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 18 EUROPE SPECIALTY CLINICS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 19 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 20 EUROPE OTHER END-USE IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 21 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 22 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 23 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 24 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 25 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 26 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 27 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 28 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 29 GERMANY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 30 GERMANY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 31 GERMANY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 32 GERMANY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 33 GERMANY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 34 GERMANY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 35 GERMANY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 36 FRANCE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 37 FRANCE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 38 FRANCE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 39 FRANCE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 40 FRANCE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 41 FRANCE FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 42 FRANCE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 43 U.K. FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 44 U.K. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 45 U.K. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 46 U.K. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 47 U.K. FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 48 U.K. FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 49 U.K. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 50 ITALY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 51 ITALY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 52 ITALY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 53 ITALY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 54 ITALY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 55 ITALY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 56 ITALY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 57 SPAIN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 58 SPAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 59 SPAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 60 SPAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 61 SPAIN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 62 SPAIN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 63 SPAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 64 RUSSIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 65 RUSSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 66 RUSSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 67 RUSSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 68 RUSSIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 69 RUSSIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 70 RUSSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 71 TURKEY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 72 TURKEY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 73 TURKEY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 74 TURKEY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 75 TURKEY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 76 TURKEY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 77 TURKEY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 78 NETHERLANDS FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 79 NETHERLANDS MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 80 NETHERLANDS MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 81 NETHERLANDS MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 82 NETHERLANDS FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 83 NETHERLANDS FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 84 NETHERLANDS MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 85 SWITZERLAND FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 86 SWITZERLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 87 SWITZERLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 88 SWITZERLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 89 SWITZERLAND FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 90 SWITZERLAND FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 91 SWITZERLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 92 HUNGARY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 93 HUNGARY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 94 HUNGARY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 95 HUNGARY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 96 HUNGARY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 97 HUNGARY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 98 HUNGARY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 99 LITHUANIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 100 LITHUANIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 101 LITHUANIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 102 LITHUANIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 103 LITHUANIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 104 LITHUANIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 105 LITHUANIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 106 AUSTRIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 107 AUSTRIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 108 AUSTRIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 109 AUSTRIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 110 AUSTRIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 111 AUSTRIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 112 AUSTRIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 113 IRELAND FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 114 IRELAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 115 IRELAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 116 IRELAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 117 IRELAND FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 118 IRELAND FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 119 IRELAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 120 NORWAY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 121 NORWAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 122 NORWAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 123 NORWAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 124 NORWAY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 125 NORWAY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 126 NORWAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 127 POLAND FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 128 POLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 129 POLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 130 POLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 131 POLAND FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 132 POLAND FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 133 POLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 134 REST OF EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

图片列表

FIGURE 1 EUROPE FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION

FIGURE 2 EUROPE FIBROTIC DISEASE TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE FIBROTIC DISEASE TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 EUROPE FIBROTIC DISEASE TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE FIBROTIC DISEASE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE FIBROTIC DISEASE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE FIBROTIC DISEASE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 EUROPE FIBROTIC DISEASE TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE FIBROTIC DISEASE TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION

FIGURE 11 EXECUTIVE SUMMARY

FIGURE 12 STRATEGIC DECISIONS

FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE EUROPE FIBROTIC DISEASE TREATMENT MARKET FROM 2025 TO 2032

FIGURE 14 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE FIBROTIC DISEASE TREATMENT MARKET IN 2025 AND 2032

FIGURE 15 MARKET OVERVIEW

FIGURE 16 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2024

FIGURE 17 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2025-2032 (USD THOUSAND)

FIGURE 18 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, CAGR (2025-2032)

FIGURE 19 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 20 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2024

FIGURE 21 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)

FIGURE 22 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, CAGR (2025-2032)

FIGURE 23 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 24 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2024

FIGURE 25 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)

FIGURE 26 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY END USER, CAGR (2025-2032)

FIGURE 27 EUROPE FIBROTIC DISEASE TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 28 EUROPE FIBROTIC DISEASE TREATMENT MARKET: SNAPSHOT (2024)

FIGURE 29 EUROPE FIBROTIC DISEASE TREATMENT MARKET: COMPANY SHARE 2024 (%)

查看详细信息

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

What is the current market value for the Europe Fibrotic Disease Treatment Market?

Europe Fibrotic Disease Treatment Market size was valued at USD 1.37 Billion in 2024.

What is the growth rate of the Europe Fibrotic Disease Treatment Market?

The Europe Fibrotic Disease Treatment Market is projected to grow at a CAGR of 6.7% from 2025 to 2032.

Which are the major market drivers for the market?

Rising prevalence of fibrotic diseases and increase in the number of people smoking cigarettes are the major drivers for the market..

What are the major companies operating in this market?

C.H. Boehringer Sohn AG & Co. KG., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Accord Healthcare, AbbVie Inc., Redx Pharma Pic, Bristol-Myers Squibb Company, BioMX, KITHER BIOTECH S.R.L., Verona Pharma pic, Intercept Pharmaceuticals, Inc., are the major companies among others operating in this market.

Which countries data is covered in the market?

The countries covered in the market are Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe.

Forecast Period	2025 –2032
Market Size (Base Year)	USD 1.37 Billion
Market Size (Forecast Year)	USD 2.29 Billion
CAGR	6.70 %
Major Markets Players	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Request For Unlock

欧洲纤维化疾病治疗市场规模、份额和趋势分析报告 – 行业概况和 2031 年预测

欧洲纤维化疾病治疗市场规模、份额和趋势分析报告 – 行业概况和 2031 年预测

Europe Fibrotic Diseases Treatment Market

CAGR : 6.70 %

纤维化疾病治疗市场分析

纤维化疾病治疗市场规模

纤维化疾病治疗市场范围

欧洲纤维化疾病治疗市场区域分析

纤维化疾病治疗市场份额

纤维化疾病治疗市场的最新发展

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

报告

市场洞察

支持

解决方案

欧洲纤维化疾病治疗市场规模、份额和趋势分析报告 – 行业概况和 2031 年预测

欧洲纤维化疾病治疗市场规模、份额和趋势分析报告 – 行业概况和 2031 年预测

Europe Fibrotic Diseases Treatment Market

CAGR : 6.70 %

纤维化疾病治疗市场分析

纤维化疾病治疗市场规模

纤维化疾病治疗市场范围

欧洲纤维化疾病治疗市场区域分析

纤维化疾病治疗市场份额

纤维化疾病治疗市场的最新发展

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

浏览相关页面